Preview

Современная ревматология

Расширенный поиск

Ритуксимаб: современная терапия ревматоидного артрита

https://doi.org/10.14412/1996-7012-2008-477

Полный текст:

Об авторе

Е. Л. Лучихина



Литература

1. <div><p>Harris E. D. Jr. Rheumatoid Arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277-89.</p><p>Emery P., Suarez-Almazor M. Rheumatoid Arthritis. Clin Evid 2003; 10: 1454-76.</p><p>Насонов Е.Л., Каратеев Д.Е., Чичасова Н.В. и др. Современные стандарты фармакотерапии ревматоидного артрита. Клин фармакология и терапия 2005; 14(1): 72-5.</p><p>Silverman G.J., Carson D.A. Roles of B cells in rheumatoid ar5thritis. Arthritis Res Ther 2003 (Suppl. 4): 1-6.</p><p>Nepom G.T. Major histocompatibility complex- directed susceptibility to rheumatoid arthritis. Adv Immunol 1998; 68: 315-32.</p><p>Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.</p><p>Bennett S.R., Falta M.T, Bill J. et al. Antigen- specific T cells in rheumatoid arthritis. Curr Rheumatol Rep 2003; 5: 255-63.</p><p>Edwards J.C.W., Cambridge G.,Abrahams V.M. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999; 97: 188-96.</p><p>Gause A., Berek C. The role of B cells in the pathogenesis of rheumatoid arthritis. Potential implications for treatment. BioDrugs 2001; 15: 73-9.</p><p>Reparon-Schuijt C.C., van Esche W.J.E., van Kooten C. et al. Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis. Arthritis Rheum 2001; 44: 2029-37.</p><p>Takemura S., Klimiuk P.A., Braun A. et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167: 4710-18.</p><p>Zhang Z., Bridges S.L. Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am 2001; 27: 335-53. Dц rner T., Burmester G.R. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 2003; 15: 246-52.</p><p>Shiokawa S., Matsumoto N., Nisimura J. Clonal analysis of B cells in the synovial membrane of patients with rheumatoid arthritis. Scand J Rheumatol 2003; 32: 12-8. Tighe H, Carson DA. Rheumatoid factors. In: Kelly WN, Rudy S, Sledge CD, Harris ED eds. Textbook of rheumatology. Philadelphia: Saunders 1997:241-9.</p><p>Van Zeben D., Hazes J.M.W., Zwinderman A.H. et al. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow-up study. Ann Rheum Dis 1992; 51: 1029-35. 16. ФАРМАКОТЕРАПИЯ</p><p>Lutt J.R., Deodhar A. Rheumatoid arthritis : strategies in the management of patients showing an inadequate response to TNFalpha antagonists. Drugs 2008; 68(5): 591-606.</p><p>Бурместер Г.-Р., Пецутто А. с участием Ульрихса Т. и Айхеро А. Наглядная иммунология. БИНОМ. Лаборатория знаний. М.: 2007: 32-44.</p><p>Anderson D.R., Grillo-Lopez A.J., Varns C. et al. Targeted anti-cancer therapy using rituximab, a chimeric anti CD-20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997; 25: 705-8.</p><p>Clynes R.A., Towers T.L., Presta L.G. et al. Inhibitory Fc receptors modulate in vivo cytotoxici-ty against tumour targets. Nat Med 2000; 6: 443-6.</p><p>Reff M.E., Carner K., Chambers K.S. et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.</p><p>McLaughlin P., Grillo-Lopez A.J., Link B.K. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.</p><p>Edwards J.C.W., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-11.</p><p>Leandro M.J., Edwards J.C.W.,Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-8.</p><p>De Vita S., Zaja F., Sacco S. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum 2002; 46: 2029-33.</p><p>Kramm H., Hansen K.E., Gowing E. Successful therapy of rheumatoid arthritis with rituximab. Renewed interest in the role of B cells in the patho-genesis of rheumatoid arthritis. J Clin Rheumatol. 2004; 10: 28-32.</p><p>Kneitz C., Wilhelm M., Tony H.P. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 2004; 33: 82-6.</p><p>Cambridge G., Leandro M.J., Edwards J.C. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-54.</p><p>Panayi G.S. B Cell-Directed Therapy in Rheumatoid Arthritis - Clinical Experience. J Rheumatol 2005; 32 (suppl. 73):19-24.</p><p>Emery P., Fillipowicz-Sosnowska A., Szczepanski L. et al. Primary analysis od a doubleblind placebo-controlled dose ranging trial of ritux-imab, an abti-CD20 monoclonal antibody in patients with rheumatoid arthritis receiving methotrexate (DANCER trial). EULAR 2005; June 8-11, 2005, Viena, Austria, OP008.</p><p>Cohen S.B., Emery P., Greenwald M.W. et al. Genovese M.C. et al., for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebocon-trolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.</p><p>Mease P.J., Revicki D.A., Szechinski J. et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008; 35: 20-30.</p><p>Keystone E., Fleischmann R., Emery P. Safety and Efficacy of Additional Courses of Rituximab in Patients With Active Rheumatoid Arthritis. An Open-Label Extension Analysis. Arthritis &amp; Rheum 2007; 56 ( No. 12, December): 3896-908.</p><p>Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis 2008 Jan 18 [Epub ahead of print].</p><p>Smolen S.J., Keystone E.C., Emery P. et al. Consensus Statement on the Use of Rituximab in Patients With Rheumatoid Arthritis. Ann Rheum Dis 2007; 66: 143-150.</p><p>Furst D.E., Breedveld F.C., Kalden J.R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007; 66 (suppl. III): 2-22.</p><p>Temprano K.K., Bandlamudi R.,Moore T.L. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005; 35: 112-21.</p><p>Assous N., Gossec L., Dieud О P. et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol. 2008; 35: 31-4.</p><p>Galarza C., Valencia D., Tobon G.J. et al. Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases? Clin Rev Allergy Immunol 2008; 34(1): 124-8.</p></div><br />


Для цитирования:


Лучихина Е.Л. Ритуксимаб: современная терапия ревматоидного артрита. Современная ревматология. 2008;2(2):74-79. https://doi.org/10.14412/1996-7012-2008-477

For citation:


Luchikhina E.L. Rituksimab: sovremennaya terapiya revmatoidnogo artrita. Modern Rheumatology Journal. 2008;2(2):74-79. (In Russ.) https://doi.org/10.14412/1996-7012-2008-477

Просмотров: 500


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)